TOVX — Theriva Biologics, Inc. Common Stock
5 mentions in the last 24 hours · 0.02% of all mentions
Why people talked about TOVX (2026-11-03)
- The company is shifting its strategic focus to the clinical development of its lead asset, VCN-01.
- Recent market activity highlights clinical trial updates for VCN-01 alongside the financial implications of the divestiture.
| Bluesky | 3 | community |
| GDELT | 1 | news |
| SEC EDGAR 8-K | 1 | filings |